Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

NIRF-Molecular Imaging with Synovial Macrophages-Targeting Vsig4 Nanobody for Disease Monitoring in a Mouse Model of Arthritis.

Zheng F, Luo S, Ouyang Z, Zhou J, Mo H, Schoonooghe S, Muyldermans S, De Baetselier P, Raes G, Wen Y.

Int J Mol Sci. 2019 Jul 8;20(13). pii: E3347. doi: 10.3390/ijms20133347.

2.

An innovative approach in the detection of Toxocara canis excretory/secretory antigens using specific nanobodies.

Morales-Yanez FJ, Sariego I, Vincke C, Hassanzadeh-Ghassabeh G, Polman K, Muyldermans S.

Int J Parasitol. 2019 Jul;49(8):635-645. doi: 10.1016/j.ijpara.2019.03.004. Epub 2019 May 29.

3.

Llama peripheral B-cell populations producing conventional and heavy chain-only IgG subtypes are phenotypically indistinguishable but immunogenetically distinct.

Henry KA, van Faassen H, Harcus D, Marcil A, Hill JJ, Muyldermans S, MacKenzie CR.

Immunogenetics. 2019 Apr;71(4):307-320. doi: 10.1007/s00251-018-01102-9. Epub 2019 Jan 18.

PMID:
30656359
4.

Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition.

Dondelinger M, Filée P, Sauvage E, Quinting B, Muyldermans S, Galleni M, Vandevenne MS.

Front Immunol. 2018 Oct 16;9:2278. doi: 10.3389/fimmu.2018.02278. eCollection 2018. Review.

5.

Guided Evolution of Recombinant Bombyx mori Acetylcholinesterase II by Homology Modeling to Change Pesticide Sensitivity.

Cai J, Wang B, Li J, Chen Z, Rao M, Muyldermans S, Hua X, Xie X, Wang H, Yang J, Xu Z, Shen Y, Sun Y.

Int J Mol Sci. 2018 Oct 27;19(11). pii: E3366. doi: 10.3390/ijms19113366.

6.

The Development and Validation of a Novel Nanobody-Based Competitive ELISA for the Detection of Foot and Mouth Disease 3ABC Antibodies in Cattle.

Gelkop S, Sobarzo A, Brangel P, Vincke C, Romão E, Fedida-Metula S, Strom N, Ataliba I, Mwiine FN, Ochwo S, Velazquez-Salinas L, McKendry RA, Muyldermans S, Lutwama JJ, Rieder E, Yavelsky V, Lobel L.

Front Vet Sci. 2018 Oct 12;5:250. doi: 10.3389/fvets.2018.00250. eCollection 2018.

7.

Nanobodies as novel therapeutic agents in envenomation.

Alirahimi E, Kazemi-Lomedasht F, Shahbazzadeh D, Habibi-Anbouhi M, Hosseininejad Chafi M, Sotoudeh N, Ghaderi H, Muyldermans S, Behdani M.

Biochim Biophys Acta Gen Subj. 2018 Dec;1862(12):2955-2965. doi: 10.1016/j.bbagen.2018.08.019. Epub 2018 Aug 30. Review.

PMID:
30309831
8.

Site-Specific Radioactive Labeling of Nanobodies.

Crauwels M, Massa S, Martin C, Betti C, Ballet S, Devoogdt N, Xavier C, Muyldermans S.

Methods Mol Biol. 2018;1827:505-540. doi: 10.1007/978-1-4939-8648-4_26.

PMID:
30196514
9.

Blocking EGFR Activation with Anti-EGF Nanobodies via Two Distinct Molecular Recognition Mechanisms.

Guardiola S, Varese M, Sánchez-Navarro M, Vincke C, Teixidó M, García J, Muyldermans S, Giralt E.

Angew Chem Int Ed Engl. 2018 Oct 15;57(42):13843-13847. doi: 10.1002/anie.201807736. Epub 2018 Sep 21.

PMID:
30152597
10.

Development of a Nanobody-based lateral flow assay to detect active Trypanosoma congolense infections.

Pinto Torres JE, Goossens J, Ding J, Li Z, Lu S, Vertommen D, Naniima P, Chen R, Muyldermans S, Sterckx YG, Magez S.

Sci Rep. 2018 Jun 13;8(1):9019. doi: 10.1038/s41598-018-26732-7.

11.

The structural basis of nanobody unfolding reversibility and thermoresistance.

Kunz P, Zinner K, Mücke N, Bartoschik T, Muyldermans S, Hoheisel JD.

Sci Rep. 2018 May 21;8(1):7934. doi: 10.1038/s41598-018-26338-z.

12.

Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting.

Samec N, Jovcevska I, Stojan J, Zottel A, Liovic M, Myers MP, Muyldermans S, Šribar J, Križaj I, Komel R.

Oncotarget. 2018 Apr 3;9(25):17282-17299. doi: 10.18632/oncotarget.24629. eCollection 2018 Apr 3.

13.

Combinatorial Design of a Nanobody that Specifically Targets Structured RNAs.

Cawez F, Duray E, Hu Y, Vandenameele J, Romão E, Vincke C, Dumoulin M, Galleni M, Muyldermans S, Vandevenne M.

J Mol Biol. 2018 May 25;430(11):1652-1670. doi: 10.1016/j.jmb.2018.03.032. Epub 2018 Apr 11.

14.

Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20.

Krasniqi A, Bialkowska M, Xavier C, Van der Jeught K, Muyldermans S, Devoogdt N, D'Huyvetter M.

N Biotechnol. 2018 Oct 25;45:69-79. doi: 10.1016/j.nbt.2018.03.004. Epub 2018 Mar 21.

PMID:
29574274
15.

Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function.

Kazemi-Lomedasht F, Muyldermans S, Habibi-Anbouhi M, Behdani M.

Iran J Basic Med Sci. 2018 Mar;21(3):260-266. doi: 10.22038/ijbms.2018.24898.6183.

16.

Structural Basis for the Specific Neutralization of Stx2a with a Camelid Single Domain Antibody Fragment.

Bernedo-Navarro RA, Romão E, Yano T, Pinto J, De Greve H, Sterckx YG, Muyldermans S.

Toxins (Basel). 2018 Mar 1;10(3). pii: E108. doi: 10.3390/toxins10030108.

17.

Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.

Sparkes A, De Baetselier P, Brys L, Cabrito I, Sterckx YG, Schoonooghe S, Muyldermans S, Raes G, Bucala R, Vanlandschoot P, Van Ginderachter JA, Stijlemans B.

FASEB J. 2018 Jun;32(6):3411-3422. doi: 10.1096/fj.201701189R. Epub 2018 Jan 25.

18.

Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.

Arezumand R, Alibakhshi A, Ranjbari J, Ramazani A, Muyldermans S.

Front Immunol. 2017 Dec 8;8:1746. doi: 10.3389/fimmu.2017.01746. eCollection 2017. Review.

19.

Inhibiting the Ca2+ Influx Induced by Human CSF.

Drews A, De S, Flagmeier P, Wirthensohn DC, Chen WH, Whiten DR, Rodrigues M, Vincke C, Muyldermans S, Paterson RW, Slattery CF, Fox NC, Schott JM, Zetterberg H, Dobson CM, Gandhi S, Klenerman D.

Cell Rep. 2017 Dec 12;21(11):3310-3316. doi: 10.1016/j.celrep.2017.11.057.

20.

Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.

Hu Y, Liu C, Muyldermans S.

Front Immunol. 2017 Nov 2;8:1442. doi: 10.3389/fimmu.2017.01442. eCollection 2017. Review.

21.

A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells.

Balhuizen A, Massa S, Mathijs I, Turatsinze JV, De Vos J, Demine S, Xavier C, Villate O, Millard I, Egrise D, Capito C, Scharfmann R, In't Veld P, Marchetti P, Muyldermans S, Goldman S, Lahoutte T, Bouwens L, Eizirik DL, Devoogdt N.

Sci Rep. 2017 Nov 9;7(1):15130. doi: 10.1038/s41598-017-15417-2.

22.

Construction of High-Quality Camel Immune Antibody Libraries.

Romão E, Poignavent V, Vincke C, Ritzenthaler C, Muyldermans S, Monsion B.

Methods Mol Biol. 2018;1701:169-187. doi: 10.1007/978-1-4939-7447-4_9.

PMID:
29116505
23.

Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma.

Krasniqi A, D'Huyvetter M, Xavier C, Van der Jeught K, Muyldermans S, Van Der Heyden J, Lahoutte T, Tavernier J, Devoogdt N.

Mol Cancer Ther. 2017 Dec;16(12):2828-2839. doi: 10.1158/1535-7163.MCT-17-0554. Epub 2017 Oct 20.

24.

Structural basis for the high specificity of a Trypanosoma congolense immunoassay targeting glycosomal aldolase.

Pinto J, Odongo S, Lee F, Gaspariunaite V, Muyldermans S, Magez S, Sterckx YG.

PLoS Negl Trop Dis. 2017 Sep 15;11(9):e0005932. doi: 10.1371/journal.pntd.0005932. eCollection 2017 Sep.

25.

Nanobody-mediated resistance to Grapevine fanleaf virus in plants.

Hemmer C, Djennane S, Ackerer L, Hleibieh K, Marmonier A, Gersch S, Garcia S, Vigne E, Komar V, Perrin M, Gertz C, Belval L, Berthold F, Monsion B, Schmitt-Keichinger C, Lemaire O, Lorber B, Gutiérrez C, Muyldermans S, Demangeat G, Ritzenthaler C.

Plant Biotechnol J. 2018 Feb;16(2):660-671. doi: 10.1111/pbi.12819. Epub 2017 Oct 6.

26.

Generation of Nanobodies against SlyD and development of tools to eliminate this bacterial contaminant from recombinant proteins.

Hu Y, Romão E, Vertommen D, Vincke C, Morales-Yánez F, Gutiérrez C, Liu C, Muyldermans S.

Protein Expr Purif. 2017 Sep;137:64-76. doi: 10.1016/j.pep.2017.06.016. Epub 2017 Jun 28.

PMID:
28668496
27.

Exploiting sequence and stability information for directing nanobody stability engineering.

Kunz P, Flock T, Soler N, Zaiss M, Vincke C, Sterckx Y, Kastelic D, Muyldermans S, Hoheisel JD.

Biochim Biophys Acta Gen Subj. 2017 Sep;1861(9):2196-2205. doi: 10.1016/j.bbagen.2017.06.014. Epub 2017 Jun 20.

28.

Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.

Kromann-Hansen T, Louise Lange E, Peter Sørensen H, Hassanzadeh-Ghassabeh G, Huang M, Jensen JK, Muyldermans S, Declerck PJ, Komives EA, Andreasen PA.

Sci Rep. 2017 Jun 13;7(1):3385. doi: 10.1038/s41598-017-03457-7.

29.

Inactivation of γ-secretases leads to accumulation of substrates and non-Alzheimer neurodegeneration.

Acx H, Serneels L, Radaelli E, Muyldermans S, Vincke C, Pepermans E, Müller U, Chávez-Gutiérrez L, De Strooper B.

EMBO Mol Med. 2017 Aug;9(8):1088-1099. doi: 10.15252/emmm.201707561.

30.

Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates.

Jovčevska I, Zupanec N, Urlep Ž, Vranič A, Matos B, Stokin CL, Muyldermans S, Myers MP, Buzdin AA, Petrov I, Komel R.

Oncotarget. 2017 Jul 4;8(27):44141-44158. doi: 10.18632/oncotarget.17390.

31.

Ultrasensitive Measurement of Ca2+ Influx into Lipid Vesicles Induced by Protein Aggregates.

Flagmeier P, De S, Wirthensohn DC, Lee SF, Vincke C, Muyldermans S, Knowles TPJ, Gandhi S, Dobson CM, Klenerman D.

Angew Chem Int Ed Engl. 2017 Jun 26;56(27):7750-7754. doi: 10.1002/anie.201700966. Epub 2017 May 5.

32.

Cytoplasmic versus periplasmic expression of site-specifically and bioorthogonally functionalized nanobodies using expressed protein ligation.

Billen B, Vincke C, Hansen R, Devoogdt N, Muyldermans S, Adriaensens P, Guedens W.

Protein Expr Purif. 2017 May;133:25-34. doi: 10.1016/j.pep.2017.02.009. Epub 2017 Feb 24.

PMID:
28238765
33.

Limiting the protein corona: A successful strategy for in vivo active targeting of anti-HER2 nanobody-functionalized nanostars.

D'Hollander A, Jans H, Velde GV, Verstraete C, Massa S, Devoogdt N, Stakenborg T, Muyldermans S, Lagae L, Himmelreich U.

Biomaterials. 2017 Apr;123:15-23. doi: 10.1016/j.biomaterials.2017.01.007. Epub 2017 Jan 6.

PMID:
28152380
34.

Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity.

Wen Y, Ouyang Z, Schoonooghe S, Luo S, De Baetselier P, Lu W, Muyldermans S, Raes G, Zheng F.

Immunobiology. 2017 Jun;222(6):807-813. doi: 10.1016/j.imbio.2016.11.008. Epub 2016 Nov 18.

PMID:
27889311
35.

Dromedary immune response and specific Kv2.1 antibody generation using a specific immunization approach.

Hassiki R, Labro AJ, Benlasfar Z, Vincke C, Somia M, El Ayeb M, Muyldermans S, Snyders DJ, Bouhaouala-Zahar B.

Int J Biol Macromol. 2016 Dec;93(Pt A):167-171. doi: 10.1016/j.ijbiomac.2016.06.031. Epub 2016 Jun 16.

PMID:
27320844
36.

Specificity Evaluation and Disease Monitoring in Arthritis Imaging with Complement Receptor of the Ig superfamily targeting Nanobodies.

Zheng F, Perlman H, Matthys P, Wen Y, Lahoutte T, Muyldermans S, Lu S, De Baetselier P, Schoonooghe S, Devoogdt N, Raes G.

Sci Rep. 2016 Oct 25;6:35966. doi: 10.1038/srep35966.

37.

Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities.

Massa S, Vikani N, Betti C, Ballet S, Vanderhaegen S, Steyaert J, Descamps B, Vanhove C, Bunschoten A, van Leeuwen FW, Hernot S, Caveliers V, Lahoutte T, Muyldermans S, Xavier C, Devoogdt N.

Contrast Media Mol Imaging. 2016 Sep;11(5):328-339. doi: 10.1002/cmmi.1696. Epub 2016 May 5.

PMID:
27147480
38.

Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.

Romao E, Morales-Yanez F, Hu Y, Crauwels M, De Pauw P, Hassanzadeh GG, Devoogdt N, Ackaert C, Vincke C, Muyldermans S.

Curr Pharm Des. 2016;22(43):6500-6518. doi: 10.2174/1381612822666160923114417. Review.

PMID:
27669966
39.

Identification and characterization of a novel nanobody against human placental growth factor to modulate angiogenesis.

Arezumand R, Mahdian R, Zeinali S, Hassanzadeh-Ghassabeh G, Mansouri K, Khanahmad H, Namvar-Asl N, Rahimi H, Behdani M, Cohan RA, Eavazalipour M, Ramazani A, Muyldermans S.

Mol Immunol. 2016 Oct;78:183-192. doi: 10.1016/j.molimm.2016.09.012. Epub 2016 Sep 17.

PMID:
27648860
40.

Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1.

Zhou X, Hendrickx ML, Hassanzadeh-Ghassabeh G, Muyldermans S, Declerck PJ.

Thromb Haemost. 2016 Nov 30;116(6):1032-1040. Epub 2016 Sep 8.

PMID:
27604413
41.

Individual aggregates of amyloid beta induce temporary calcium influx through the cell membrane of neuronal cells.

Drews A, Flint J, Shivji N, Jönsson P, Wirthensohn D, De Genst E, Vincke C, Muyldermans S, Dobson C, Klenerman D.

Sci Rep. 2016 Aug 24;6:31910. doi: 10.1038/srep31910.

42.

Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis.

Zheng F, Sparkes A, De Baetselier P, Schoonooghe S, Stijlemans B, Muyldermans S, Flamand V, Van Ginderachter JA, Devoogdt N, Raes G, Beschin A.

Mol Imaging Biol. 2017 Feb;19(1):49-58. doi: 10.1007/s11307-016-0976-3.

PMID:
27339464
43.

A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior.

Kromann-Hansen T, Oldenburg E, Yung KW, Ghassabeh GH, Muyldermans S, Declerck PJ, Huang M, Andreasen PA, Ngo JC.

J Biol Chem. 2016 Jul 15;291(29):15156-68. doi: 10.1074/jbc.M116.732503. Epub 2016 May 23.

44.

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.

Dekempeneer Y, Keyaerts M, Krasniqi A, Puttemans J, Muyldermans S, Lahoutte T, D'huyvetter M, Devoogdt N.

Expert Opin Biol Ther. 2016 Aug;16(8):1035-47. doi: 10.1080/14712598.2016.1185412. Epub 2016 May 19. Review.

45.

Emerging site-specific bioconjugation strategies for radioimmunotracer development.

Massa S, Xavier C, Muyldermans S, Devoogdt N.

Expert Opin Drug Deliv. 2016 Aug;13(8):1149-63. doi: 10.1080/17425247.2016.1178235. Epub 2016 May 13. Review.

PMID:
27116898
46.

Distinct antibody species: structural differences creating therapeutic opportunities.

Muyldermans S, Smider VV.

Curr Opin Immunol. 2016 Jun;40:7-13. doi: 10.1016/j.coi.2016.02.003. Epub 2016 Feb 27. Review.

47.

An Anti-proteome Nanobody Library Approach Yields a Specific Immunoassay for Trypanosoma congolense Diagnosis Targeting Glycosomal Aldolase.

Odongo S, Sterckx YG, Stijlemans B, Pillay D, Baltz T, Muyldermans S, Magez S.

PLoS Negl Trop Dis. 2016 Feb 2;10(2):e0004420. doi: 10.1371/journal.pntd.0004420. eCollection 2016 Feb.

48.

Structural Insights into Polymorphic ABO Glycan Binding by Helicobacter pylori.

Moonens K, Gideonsson P, Subedi S, Bugaytsova J, Romaõ E, Mendez M, Nordén J, Fallah M, Rakhimova L, Shevtsova A, Lahmann M, Castaldo G, Brännström K, Coppens F, Lo AW, Ny T, Solnick JV, Vandenbussche G, Oscarson S, Hammarström L, Arnqvist A, Berg DE, Muyldermans S, Borén T, Remaut H.

Cell Host Microbe. 2016 Jan 13;19(1):55-66. doi: 10.1016/j.chom.2015.12.004.

49.

Nanobodies as Probes for Protein Dynamics in Vitro and in Cells.

Dmitriev OY, Lutsenko S, Muyldermans S.

J Biol Chem. 2016 Feb 19;291(8):3767-75. doi: 10.1074/jbc.R115.679811. Epub 2015 Dec 16. Review.

50.

Development of a high affinity Affibody-derived protein against amyloid β-peptide for future Alzheimer's disease therapy.

De Genst E, Muyldermans S.

Biotechnol J. 2015 Sep;10(11):1668-9. doi: 10.1002/biot.201500405. Epub 2015 Sep 10. No abstract available.

PMID:
26356678

Supplemental Content

Loading ...
Support Center